Literature DB >> 23940276

Immune tolerance negatively regulates B cells in knock-in mice expressing broadly neutralizing HIV antibody 4E10.

Colleen Doyle-Cooper1, Krystalyn E Hudson1, Anthony B Cooper1, Takayuki Ota1, Patrick Skog1, Phillip E Dawson2, Michael B Zwick1, William R Schief1,3,4, Dennis R Burton1,3,4,5, David Nemazee1.   

Abstract

A major goal of HIV research is to develop vaccines reproducibly eliciting broadly neutralizing Abs (bNAbs); however, this has proved to be challenging. One suggested explanation for this difficulty is that epitopes seen by bNAbs mimic self, leading to immune tolerance. We generated knock-in mice expressing bNAb 4E10, which recognizes the membrane proximal external region of gp41. Unlike b12 knock-in mice, described in the companion article (Ota et al. 2013. J. Immunol. 191: 3179-3185), 4E10HL mice were found to undergo profound negative selection of B cells, indicating that 4E10 is, to a physiologically significant extent, autoreactive. Negative selection occurred by various mechanisms, including receptor editing, clonal deletion, and receptor downregulation. Despite significant deletion, small amounts of IgM and IgG anti-gp41 were found in the sera of 4E10HL mice. On a Rag1⁻/⁻ background, 4E10HL mice had virtually no serum Ig of any kind. These results are consistent with a model in which B cells with 4E10 specificity are counterselected, raising the question of how 4E10 was generated in the patient from whom it was isolated. This represents the second example of a membrane proximal external region-directed bNAb that is apparently autoreactive in a physiological setting. The relative conservation in HIV of the 4E10 epitope might reflect the fact that it is under less intense immunological selection as a result of B cell self-tolerance. The safety and desirability of targeting this epitope by a vaccine is discussed in light of the newly described bNAb 10E8.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23940276      PMCID: PMC3773228          DOI: 10.4049/jimmunol.1301285

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  37 in total

1.  Characterization of molecular features, antigen-binding, and in vitro properties of IgG and IgM variants of 4E10, an anti-HIV type 1 neutralizing monoclonal antibody.

Authors:  Renate Kunert; Susanne Wolbank; Gabriela Stiegler; Robert Weik; Hermann Katinger
Journal:  AIDS Res Hum Retroviruses       Date:  2004-07       Impact factor: 2.205

2.  Peripheral deletion of self-reactive B cells.

Authors:  D M Russell; Z Dembić; G Morahan; J F Miller; K Bürki; D Nemazee
Journal:  Nature       Date:  1991-11-28       Impact factor: 49.962

3.  Immunoglobulin heavy chain gene replacement: a mechanism of receptor editing.

Authors:  C Chen; Z Nagy; E L Prak; M Weigert
Journal:  Immunity       Date:  1995-12       Impact factor: 31.745

4.  Common tolerance mechanisms, but distinct cross-reactivities associated with gp41 and lipids, limit production of HIV-1 broad neutralizing antibodies 2F5 and 4E10.

Authors:  Yao Chen; Jinsong Zhang; Kwan-Ki Hwang; Hilary Bouton-Verville; Shi-Mao Xia; Amanda Newman; Ying-Bin Ouyang; Barton F Haynes; Laurent Verkoczy
Journal:  J Immunol       Date:  2013-07-03       Impact factor: 5.422

5.  Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

Authors:  M B Zwick; A F Labrijn; M Wang; C Spenlehauer; E O Saphire; J M Binley; J P Moore; G Stiegler; H Katinger; D R Burton; P W Parren
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

6.  Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope.

Authors:  Gilad Ofek; Min Tang; Anna Sambor; Hermann Katinger; John R Mascola; Richard Wyatt; Peter D Kwong
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

7.  Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site.

Authors:  P W Parren; H J Ditzel; R J Gulizia; J M Binley; C F Barbas; D R Burton; D E Mosier
Journal:  AIDS       Date:  1995-06       Impact factor: 4.177

8.  Rearrangement of upstream DH and VH genes to a rearranged immunoglobulin variable region gene inserted into the DQ52-JH region of the immunoglobulin heavy chain locus.

Authors:  S Taki; F Schwenk; K Rajewsky
Journal:  Eur J Immunol       Date:  1995-07       Impact factor: 5.532

9.  Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization.

Authors:  A Buchacher; R Predl; K Strutzenberger; W Steinfellner; A Trkola; M Purtscher; G Gruber; C Tauer; F Steindl; A Jungbauer
Journal:  AIDS Res Hum Retroviruses       Date:  1994-04       Impact factor: 2.205

10.  Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow.

Authors:  R R Hardy; C E Carmack; S A Shinton; J D Kemp; K Hayakawa
Journal:  J Exp Med       Date:  1991-05-01       Impact factor: 14.307

View more
  66 in total

Review 1.  Minding the gap: The impact of B-cell tolerance on the microbial antibody repertoire.

Authors:  Joel Finney; Akiko Watanabe; Garnett Kelsoe; Masayuki Kuraoka
Journal:  Immunol Rev       Date:  2019-09-27       Impact factor: 12.988

Review 2.  Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design.

Authors:  Dennis R Burton; Lars Hangartner
Journal:  Annu Rev Immunol       Date:  2016-05-20       Impact factor: 28.527

3.  Peripheral Membrane Interactions Boost the Engagement by an Anti-HIV-1 Broadly Neutralizing Antibody.

Authors:  Edurne Rujas; José M M Caaveiro; Sara Insausti; Miguel García-Porras; Kouhei Tsumoto; José L Nieva
Journal:  J Biol Chem       Date:  2017-02-17       Impact factor: 5.157

Review 4.  Basics of memory B-cell responses: lessons from and for the real world.

Authors:  Rachel Wong; Deepta Bhattacharya
Journal:  Immunology       Date:  2018-11-29       Impact factor: 7.397

5.  Human Rhinovirus Presenting 4E10 Epitope of HIV-1 MPER Elicits Neutralizing Antibodies in Human ICAM-1 Transgenic Mice.

Authors:  Guohua Yi; Xiongying Tu; Preeti Bharaj; Hua Guo; Junli Zhang; Premlata Shankar; N Manjunath
Journal:  Mol Ther       Date:  2015-06-10       Impact factor: 11.454

Review 6.  Adeno-associated virus delivery of broadly neutralizing antibodies.

Authors:  Bruce C Schnepp; Philip R Johnson
Journal:  Curr Opin HIV AIDS       Date:  2014-05       Impact factor: 4.283

7.  Structure of an HIV-1-neutralizing antibody target, the lipid-bound gp41 envelope membrane proximal region trimer.

Authors:  Patrick N Reardon; Harvey Sage; S Moses Dennison; Jeffrey W Martin; Bruce R Donald; S Munir Alam; Barton F Haynes; Leonard D Spicer
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-13       Impact factor: 11.205

8.  Potent and broad HIV-neutralizing antibodies in memory B cells and plasma.

Authors:  LaTonya D Williams; Gilad Ofek; Sebastian Schätzle; Jonathan R McDaniel; Xiaozhi Lu; Nathan I Nicely; Liming Wu; Caleb S Lougheed; Todd Bradley; Mark K Louder; Krisha McKee; Robert T Bailer; Sijy O'Dell; Ivelin S Georgiev; Michael S Seaman; Robert J Parks; Dawn J Marshall; Kara Anasti; Guang Yang; Xiaoyan Nie; Nancy L Tumba; Kevin Wiehe; Kshitij Wagh; Bette Korber; Thomas B Kepler; S Munir Alam; Lynn Morris; Gift Kamanga; Myron S Cohen; Mattia Bonsignori; Shi-Mao Xia; David C Montefiori; Garnett Kelsoe; Feng Gao; John R Mascola; M Anthony Moody; Kevin O Saunders; Hua-Xin Liao; Georgia D Tomaras; George Georgiou; Barton F Haynes
Journal:  Sci Immunol       Date:  2017-01-27

Review 9.  Immunological tolerance as a barrier to protective HIV humoral immunity.

Authors:  Kristin Ms Schroeder; Amanda Agazio; Raul M Torres
Journal:  Curr Opin Immunol       Date:  2017-07-17       Impact factor: 7.486

10.  AIDS/HIV. Host controls of HIV neutralizing antibodies.

Authors:  Barton F Haynes; Laurent Verkoczy
Journal:  Science       Date:  2014-05-09       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.